This page shows the latest Sanofi Pasteur news and features for those working in and with pharma, biotech and healthcare.
Sanofi Pasteur and Sanofi Genzyme will unite under the new brand image. ... Sanofi Pasteur and Sanofi Genzyme are focused on providing specialised care and vaccine research, respectively and will come together following the new branding as one united
These preliminary data show we have a strong booster candidate, whatever primary vaccine you have received.” said Sanofi Pasteur’s Thomas Triomphe. ... The 10, 000 participants will receive two doses of the Sanofi-GSK vaccine with efficacy assessed
The acquisition brings Origimm’s ORI-001 vaccine candidate against acne vulgaris into Sanofi’s vaccine pipeline, building its strength in mRNA technology. ... head of Sanofi Pasteur.
Trial data validates Sanofi’s mRNA and lipid nanoparticle platform but the company will not pursue its own mRNA COVID-19 vaccine. ... These results will clearly help inform the path forward for our mRNA development programmes,” said global R&D chief
Sanofi and Translate are investigating three different dose levels of the vaccine candidate – 15µg, 45µg or 135µg. ... During the COVID-19 pandemic, mRNA technologies demonstrated potential to deliver new vaccines faster than ever before,” said
Sanofi and Translate will investigate three different dose levels of the vaccine candidate – 15µg, 45µg or 135µg. ... Sanofi Pasteur.
More from news
Approximately 13 fully matching, plus 151 partially matching documents found.
In particular the largest deal this month, between MedImmune and Sanofi Pasteur, has a headline figure of $650m, a figure which would have had the deal struggling to get into the ... Headline. $m. AstraZeneca/ MedImmune. Sanofi Pasteur. Joint Development.
Sanofi Pasteur MSD previously required upwards of nine months to bring approved commercial content to market in many of its largest markets. ... Sanofi Pasteur MSD also projects overall efficiency gains of 17% in year one and 33% annually in years two
225. CureVac/ Sanofi Pasteur. Exercise of option, licence. RNActive vaccine technology vs undisclosed pathogens (preclinical).
Scandinavia. CureVac's relationship with Sanofi Pasteur dates back to 2011 when the companies entered into a collaboration and option agreement covering mRNA-based vaccines generated using CureVac's RNActive technology ... Sanofi Pasteur has now
26.6. ‡SK Chemicals/ Sanofi Pasteur. Collaboration. Pneumococcal conjugate vaccine (PCV). 23. ... Japan . Outside US, Canada. ‡ Sanofi Pasteur has rights outside Korea; SK has exclusive rights for Korea. ‡‡
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Carouge, who also becomes a member of Sanofi’s executive committee, will be at the helm of accelerating the transformation of the company. ... for Sanofi Pasteur since 2009.
Meanwhile, Joanna Troman (pictured left) moves to STEM as a project director following 10 years as Sanofi Pasteur MSD in a number of roles across marketing, strategic planning and market research.
Prior to Hill &Knowlton, Marchand served Sanofi, where she worked on French Parliament relations and she has held several positions within the French administration working for general secretariat for European affairs ... In her new role, Marchand will
Tarplee has over 30 years of life science industry experience and previously worked for the likes of Adherium, ALK Abello, Sanofi and Abbott. ... Lim previously worked at Novartis and Sanofi Pasteur, and most recently served at Takeda Pharmaceuticals as
He joins Portland from MHP Communications, where his two-year stint saw him rise to a senior account manager role and included a secondment to Sanofi Pasteur MSD’s comms team.
More from appointments
Approximately 1 fully matching, plus 16 partially matching documents found.
3, 4. The award-winning Sanofi Pasteur ‘Share the Moment’ disease awareness campaign was developed using insights gained from intensive qualitative and quantitative research into the underlying causes and beliefs surrounding
The majority of Jo’s 15 years within pharma were spent at Sanofi Pasteur MSD where she held a number of senior marketing roles before moving agency-side to STEM, holding
Sam previously held positions at Monitor and Sanofi Pasteur MSD (Merck Sharp &Dohme).
Adam Goodband joined emotive as a Strategic Planner in January 2014, having previously worked as a Medical Writer at Sanofi Pasteur MSD, has been promoted to Senior Strategic Planner.
emotive are pleased to announce the addition of former Sanofi Pasteur MSD medical writer to the team. ... Having experienced working alongside emotive as a medical writer for Sanofi Pasteur MSD, Adam was keen to join the team and bring his skills and
More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.
We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....